Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 4/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15564047 | 0.92 | SLC6A2 (0.39) | SLC6A2SLC6A4MGLLTACR1MRGPRX1 | |
| SCHEMBL16225213 | 0.83 | SLC6A2 (0.43) | SLC6A2SLC6A4MGLLTACR1MRGPRX1 | |
| SCHEMBL4693798 | 0.77 | ENPP2 (0.48) | ENPP2GRM4GSK3BKMT2AMEN1 | |
| SCHEMBL11601220 | 0.77 | ENPP2 (0.48) | ENPP2GRM4GSK3BKMT2AMEN1 | |
| SCHEMBL4386224 | 0.76 | IDO1 (0.57) | SLC6A2SLC6A4MGLLTACR1MRGPRX1 | |
| SCHEMBL4697927 | 0.75 | S1PR1 (0.45) | SLC6A2SLC6A4ENPP2GRM4GSK3B | |
| SCHEMBL6540746 | 0.75 | S1PR1 (0.45) | SLC6A2SLC6A4ENPP2GRM4GSK3B | |
| SCHEMBL8949484 | 0.75 | GSK3B (0.49) | SLC6A2SLC6A4ENPP2GRM4GSK3B | |
| SCHEMBL6481575 | 0.75 | S1PR1 (0.45) | SLC6A2SLC6A4ENPP2GRM4GSK3B | |
| SCHEMBL19707722 | 0.74 | NOTUM (0.46) | SLC6A2SLC6A4MGLLEPHX1GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563732-B2 | Oxyimino compounds and the use thereof | SHIONOGI & CO., LTD. (JP) | 2013-10-22 | — | — | US | disclosed |
| EP-2164325-B1 | OXYIMINO COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO (JP) | 2013-04-24 | — | — | EP | disclosed |
| US-20100240703-A1 | OXYIMINO COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2010-09-23 | — | — | US | disclosed |
| EP-2164325-A1 | OXYIMINO COMPOUNDS AND THE USE THEREOF | Shionogi&Co., Ltd. (JP) | 2010-03-24 | — | — | EP | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| EP-2040698-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008150470-A1 | OXYIMINO COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | SLC6A2 1326/4885SLC6A4 446/4885MGLL 3394/4885 |
| US-20100240703-A1 | OXYIMINO COMPOUNDS AND THE USE THEREOF | CACNA1A, CACNA1S, OPRM1 | SLC6A2 663/4885SLC6A4 684/4885MGLL 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.